21,479 Shares in Pfizer Inc. (NYSE:PFE) Acquired by Tyche Wealth Partners LLC

Tyche Wealth Partners LLC bought a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 4th quarter, HoldingsChannel.com reports. The firm bought 21,479 shares of the biopharmaceutical company’s stock, valued at approximately $618,000.

Other hedge funds also recently modified their holdings of the company. Moneta Group Investment Advisors LLC lifted its stake in Pfizer by 89,592.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after acquiring an additional 160,963,976 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 10.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after purchasing an additional 9,393,992 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Pfizer by 0.4% during the third quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after purchasing an additional 348,628 shares during the period. Norges Bank purchased a new position in Pfizer during the fourth quarter valued at approximately $3,150,472,000. Finally, Massachusetts Financial Services Co. MA increased its stake in Pfizer by 9.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock valued at $1,997,083,000 after buying an additional 5,185,453 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE traded down $0.22 during trading hours on Wednesday, hitting $25.69. The stock had a trading volume of 28,885,313 shares, compared to its average volume of 33,467,946. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $41.33. The stock has a market capitalization of $145.47 billion, a price-to-earnings ratio of 71.36, a P/E/G ratio of 1.18 and a beta of 0.61. The company’s fifty day moving average is $27.23 and its two-hundred day moving average is $28.79. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The company had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the prior year, the business earned $1.14 earnings per share. The business’s revenue for the quarter was down 41.3% on a year-over-year basis. On average, analysts anticipate that Pfizer Inc. will post 2.22 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on PFE. TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research note on Thursday, January 4th. Guggenheim began coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price on the stock. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.